Cobalt(III) dibromo-BODIPY-8-hydroxyquinolinate for mitochondria-targeted red light photodynamic therapy

Jana, A and Sahoo, S and Paul, S and Sahoo, S and Jayabaskaran, C and Chakravarty, AR (2023) Cobalt(III) dibromo-BODIPY-8-hydroxyquinolinate for mitochondria-targeted red light photodynamic therapy. In: Polyhedron, 245 .

PDF pol_245_2023.pdf - Published Version Restricted to Registered users only Download (3MB) | Request a copy

Abstract

The photophysical properties of boron-dipyrromethene (BODIPY) dyes have made them suitable for cellular imaging and photodynamic therapy (PDT). The efficacy of these dyes can be augmented by designing their dibromo/diiodo derivatives. Heteroleptic Co(III) complexes of a tetradentate N,N,N,O-donor polypyridyl phenolate (HL) and bidentate N,O-donor 8-hydroxyquinoline (HL1) and its BODIPY (HL2) or dibromo-BODIPY (HL3) pendants, [CoIII(L)(L1−3)]X (1–3) (where X = ClO4 for 1, 2 and Cl for 3) were synthesized and studied. The dibromo-BODIPY ligand HL3 was structurally characterized. The dibromo-BODIPY complex 3, showing singlet oxygen quantum yield (ϕΔ) value of ∼0.25, displayed remarkable apoptotic photo-cytotoxicity in HeLa cancer cells upon red light (600–720 nm) irradiation giving half-maximal inhibitory concentration (IC50) value of 0.36 μM (photocytotoxicity index: >277). It was less toxic in normal cells. Cellular imaging studies revealed mitochondrial colocalization. This work exemplifies Co(III)–dibromo-BODIPY complex as a new class of metal-based PDT agent with higher efficacy than the dyes alone. © 2023 Elsevier Ltd

Item Type:	Journal Article
Publication:	Polyhedron
Publisher:	Elsevier Ltd
Additional Information:	The copyright for this article belongs to the Elsevier Ltd.
Department/Centre:	Division of Biological Sciences > Biochemistry Division of Chemical Sciences > Inorganic & Physical Chemistry
Date Deposited:	10 Nov 2023 10:23
Last Modified:	10 Nov 2023 10:23
URI:	https://eprints.iisc.ac.in/id/eprint/83183

Actions (login required)

View Item